Tempus publishes study highlighting benefits of concurrent rna and dna sequencing in advanced cancer care

Chicago--(business wire)--tempus ai, inc. (nasdaq: tem), a technology company leading the adoption of ai to advance precision medicine and patient care, today announced publication of its study, “actionable structural variant detection via rna-ngs and dna-ngs in patients with advanced non-small cell lung cancer,” in jama network open. tempus recently conducted a retrospective study of more than 5,500 patients with advanced non-small cell lung cancer (nsclc) and found that concurrent rna- and dn.
TEM Ratings Summary
TEM Quant Ranking